Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.74 +2.86 (+6.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 Next >
News headline image
No One Told These 3 Stocks It’s a Down Week
At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space. 
Via MarketBeat
Topics Economy Electric Vehicles
News headline image
MarketBeat: Week in Review 8/1 - 8/5
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow. 
Via MarketBeat
Topics Economy Electric Vehicles
News headline image
Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment 
Via MarketBeat
News headline image
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
News headline image
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.